Menu
← Oncology Approval Tracker
FDA DECISION ·
Calquence
acalabrutinib · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
As a single agent for adults with mantle cell lymphoma after at least one prior therapy.
LAMPGEN ANALYSIS
Why it matters
FDA converted the previously treated single-agent use from accelerated to traditional approval alongside a distinct first-line combination action.
What research teams should watch
Preserve the two uses as separate eligibility rules, including whether the patient has received any previous therapy.
PRIMARY RECORDS